Neogenomics Stock News

Over the past 3 months, 8 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a comp

NeoGenomics Inc. Chief Executive Mark Mallon stepped down Monday as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, s

Cancer-testing company NeoGenomics is down more than 30% today after lowering earnings expectations. How far will NEO stock fall?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug Pfizer, Inc.

NeoGenomics Inc's (NASDAQ: NEO) CEO Mark Mallon will step down as CEO and member of the Board, effective immediately.  The Board has retained Russell Reynolds to search for the Company's next CEO T

NeoGenomics Inc. Chief Executive Mark Mallon stepped down Monday as the health-testing company revealed that first-quarter financials will miss guidance and rescinded its forecast for the full year, s

Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.

Companies Reporting Before The Bell • Despegar.com (NYSE: DESP ) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares UltraShort Russell2000 (NYSE: TWM ) is expected to report earnings for its fourth quarter. • Vivid Seats (NASDAQ: SEAT ) is projected to report quarterly loss at $0.07 per share on revenue of $139.54 million. • LumiraDx (NASDAQ: LMDX ) is expected to report quarterly loss at $0.09 per share on revenue of $69.60 million. • Life Time Group Hldgs (NYSE: LTH ) is expected to report quarterly loss at $0.41 per share on revenue of $356.92 million. • ATRenew (NYSE: RERE ) is likely to report quarterly loss at $0.03 per share on revenue of $368.91 million. • FuelCell Energy (NASDAQ: FCEL ) is estimated to report quarterly loss at $0.05 per share on revenue of $26.73 million. • Zealand Pharma (NASDAQ: ZEAL ) is expected to report quarterly loss at $0.93 per share on revenue of $11.98 million. • Yatsen Holding (NYSE: YSG ) is projected to report quarterly loss at $0.

FT MYERS, FL / ACCESSWIRE / March 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announce

Sector ETF report for PSCH

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here.

SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading. Raymond James cut the price target on Neo

NeoGenomics (NEO) delivered earnings and revenue surprises of -7.69% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?